Healthcare Industry News: treatment planning
News Release - May 7, 2009
Roswell Park Cancer Institute Leads Radiosurgery Capabilities in New York State with Leksell Gamma Knife PerfexionATLANTA and BUFFALO, N.Y., May 7 -- (Healthcare Sales & Marketing Network) -- Roswell Park Cancer Institute (RPCI) is the first center in New York state to install Elekta's Leksell Gamma Knife(R) Perfexion(TM), an advanced radiosurgery device specifically designed to treat one or more lesions in the head in a single session.
An alternative to open-brain surgery and daily radiation treatments, Gamma Knife Perfexion uses focused doses of radiation, without making a single incision, to treat brain tumors, as well as other brain disorders. This unmatched method provides pinpoint accuracy, high efficiency and outstanding results. Patients benefit from fast, painless treatment, often conducted in an outpatient surgical setting without the need for general anesthesia or even convalescence.
The newest installation was purchased in collaboration with fundraising support from donors across Western New York. Donations also will support a lectureship to bring international leaders in the field together to share best practices.
Dheerendra Prasad, MD, MCh, is Director of the Gamma Knife Program at RPCI. "For the past decade I have been actively involved in the design, development and refinement of the software and hardware associated with this technology," says Prasad. "This latest version of Leksell Gamma Knife incorporates features for added safety and accuracy and sets a new standard of quality in the field of radiosurgery."
Perfexion uses a computer-controlled table to move patients into treatment position, and a larger, fully automated helmet collimator system. These advances provide more comfort to patients and eliminate the need for time-consuming adjustments when treating multiple lesions, thereby reducing treatment times.
"This technology offers another treatment option to patients diagnosed with recurrent head and neck cancers, enabling them to avoid a major surgery, in some cases to receive radiation a second time after having a prior therapy," adds Prasad.
Roswell Park is one of the nation's top five programs treating more than 300 patients a year.
About Roswell Park Cancer Institute
Roswell Park Cancer Institute, founded in 1898, is the nation's first cancer research, treatment and education center. The Institute was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. RPCI is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit http://www.roswellpark.org/, call 1-877-ASK-RPCI (1-877-275-7724) or email email@example.com.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.